Reports Q3 revenue $611,174 vs. $414,250 last year. “Over the past quarter we continued to see encouraging preclinical data across our DNase platform modalities that is advancing our programs toward first-in-human clinical studies. This data is bolstering our belief in the potential of this innovative immune-oncology platform to deliver a much-needed treatment option to hard-to-treat patients,” commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic. “Additionally, we remain committed to expanding our development capabilities and resources through partnerships in order to potentially accelerate our development timelines, including efforts to advance toward a Phase 1 study for the treatment of pancreatic carcinoma, our lead indication.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on XBIO: